Incannex adds four OSA experts to IHL-42X advisory board; Phase 2 data July 2025

Incannex Healthcare Inc.

Appointed Scott Sands, Ali Azarbarzin, Lora McGill, and Nancy Collop to the IHL-42X Clinical Advisory Board.
Company expects to announce IHL-42X Phase 2 topline data in July 2025.
Phase 3 US study planned to start later in 2025.
IHL-42X is an oral once-daily treatment for obstructive sleep apnea (OSA).

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.